Latest Organochem Acquisition Expands GD3’s Preclinical Chemistry Services Market

After the acquisition of New England Discovery Partners (NEDP) last 2019 and Comparative Biosciences, Inc. (CBI) last 2021 by Genesis Biotechnology Group (GBG), the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development^TM (GD³) continues to expand with Genesis Axis’ latest acquisition of Organochem just this 10th of January 2023. GD³ is managed by Genesis Global Group (GGG) in the United States, while internationally, Genesis Axis does the same job seamlessly.

About the Newest GD³ Member

European international science-based chemical company Organochem is known for its massive array of services and products on smart chemistry that enables a global clientele of biotechnology and pharmaceutical companies for the engineering of novel xenobiotics and bioactive products.

Organochem oversees its international operations from its headquarters in Budapest, Hungary, with the help of a group of highly talented and motivated employees who recognize the value of excellent customer service, especially when it comes to promptly answering questions about their goods and services as well as any general inquiries. Modern information and communication technology is fully utilized by Organochem to save costs and provide customers with a high-quality, adaptable, and responsive service. By offering a service that provides items at a cost-effective pricing and within needed timeframes, they want to improve your development process. Organochem is a preferred partner in outsourcing a variety of discovery and development projects due to a distinctive fusion of a strong scientific background, efficient work practices, and robust production facilities.

Preclinical Chem at Full Power

Organochem has a fantastic opportunity to collaborate with a fully integrated contract research firm by joining the Genesis Axis and GD³. Through this agreement, Organochem will be able to offer its distinctive chemistry services to major pharmaceutical firms’ drug discovery programs in new international locations. As a member of Genesis Axis, Organochem is anticipated to experience considerable growth and development of its highly specialized business lines thanks to the expertise and dedication of its staff. According to Zoltán Dalicsek, Ph.D., CEO of Organochem, this acquisition shows that Genesis Axis is aware of and highly values the outcomes that Organochem has produced.

By enhancing their chemistry skills and expediting the screening, selection, and advancement of their industry partners’ drug candidates, this portfolio expansion will allow the GD³ member businesses to broaden their full-service drug research and discovery offerings. World-class chemists from Organochem will collaborate effectively with GD³‘s current Ultra-High-Throughput Screening (uHTS), computational, medicinal, and structural biology chemistry services platform.

Excitement from the C-Suite

The newest addition to the GD³ portfolio, according to GGG’s Director of Corporate Development Ben Bandaru, Ph.D., MBA, offers additional services that enable expansion into untapped markets and the company’s ongoing worldwide scaling. The purchase of Organochem is in line with GD³‘s goal of building an even more effective and integrated worldwide network for its business partners.

Dr. Joyce Huang, Ph.D., Chief Scientific Officer of GD³, chimes in and says that to progress the partners’ activities, Organochem’s experts will work with GD³‘s highly qualified synthetic and medicinal chemists.

The CEO of Genesis Axis and GGG, Dr. Eli Mordechai, underlines the firms’ continued dedication to improving their services for the global pharmaceutical and biotechnology communities. It is anticipated that the inclusion of Organochem’s industry knowledge and global footprint will enable Genesis Axis and GGG to differentiate their capabilities and will greatly improve GD³‘s catalog of chemical services to better serve the industry partners of the multinational conglomerate.

About Organochem

Organochem is a provider of unique synthons, building blocks, a fragment-based library, tiny, specialized libraries, and building blocks to the pharmaceutical, biotechnology, and agrochemical sectors. To facilitate the development of novel pharmaceuticals and other bioactive products, Organochem is dedicated to offering a wide range of smart chemical solutions. Organochem is a favored partner in outsourcing research and development projects due to its broad variety of cost-effective services that are based on profound science and its cutting-edge production facilities.

About Genesis Biotechnology Group

The mission of the Genesis Biotechnology Group (GBG), a group of vertically integrated businesses, is to enhance patient care by fusing their knowledge, commitment, and vision in the areas of drug discovery, individualized and customized clinical diagnostics, state-of-the-art integrated services for women’s health care, and the creation, production, and distribution of distinctive biotechnology-based products.

About Genesis Global Group and Genesis Axis

A privately held group of vertically integrated domestic and international businesses, Genesis Global Group (GGG) (USA) and Genesis Axis (International), provides in-depth knowledge, unbiased solutions, specialized products, and unmatched service across the biotechnology, health care, manufacturing, real estate, and hospitality industries. By pushing the frontiers of several industries to offer organizations and people insights and services that are anchored in innovation and unwavering quality, GGG and Genesis Axis want to create a better and healthier world for everyone.

About Genesis Drug Discovery & Development

The fully integrated CRO Genesis Drug Discovery & Development (GD³) supports our clients’ drug discovery programs from target identification through IND submission and management of Phase I–III clinical trials. The GD³ portfolio of services for the regulatory approval of novel drug and medical device products comprises services for HTS and assay development, synthetic organic and medicinal chemistry, DMPK/in-vivo pharmacology and safety pharmacology, toxicology, and clinical trial services.

Please visit www.gd3services.com to learn more.

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES